Genentech disappointed with FDA ODAC’s recommendation against Avastin
Genentech disappointed with FDA ODAC’s recommendation against Avastin
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin’s U.S. label.
Read more on News-Medical-Net
Categories: High Risk Breast Cancer Tags: against, Avastin, disappointed, Genentech, ODAC's, Recommendation